Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428189 | 1.00 | MTNR1A (0.53) | MTNR1ASMYD3MAPTGAAKDM4E | |
| SCHEMBL30358033 | 1.00 | MTNR1A (0.53) | MTNR1ASMYD3MAPTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL6531864 | 0.99 | MTNR1A (0.52) | MTNR1ASMYD3MAPTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL5849580 | 0.99 | MTNR1A (0.52) | MTNR1ASMYD3MAPTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL5849581 | 0.99 | MTNR1A (0.52) | MTNR1ASMYD3MAPTGAAKDM4E | |
| SCHEMBL30357968 | 0.89 | MTNR1A (0.51) | MTNR1ASMYD3MAPTGAAALDH1A1 | |
| SCHEMBL30358016 | 0.87 | MTNR1A (0.49) | MTNR1ASMYD3MAPTGAAKDM4E | |
| SCHEMBL10334541 | 0.85 | GAA (0.59) | MTNR1AMAPTGAAKDM4EBRD4 | |
| SCHEMBL3182006 | 0.85 | GAA (0.59) | MTNR1AMAPTGAAKDM4EBRD4 | |
| SCHEMBL30213277 | 0.85 | GAA (0.59) | MTNR1AMAPTGAAKDM4EBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2005023799-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | MTNR1A 3015/4885SMYD3 2731/4885MAPT 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.